156 related articles for article (PubMed ID: 37408209)
21. Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.
Tian J; Raffa FA; Dai M; Moamer A; Khadang B; Hachim IY; Bakdounes K; Ali S; Jean-Claude B; Lebrun JJ
Br J Cancer; 2018 Dec; 119(12):1495-1507. PubMed ID: 30482914
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
23. SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells.
Ribeiro AS; Nobre AR; Mendes N; Almeida J; Vieira AF; Sousa B; Carvalho FA; Monteiro J; Polónia A; Fonseca M; Sanches JM; Santos NC; Seruca R; Paredes J
Cell Commun Signal; 2018 Nov; 16(1):75. PubMed ID: 30404626
[TBL] [Abstract][Full Text] [Related]
24. Regulation of the prometastatic neuregulin-MMP13 axis by SRC family kinases: therapeutic implications.
Orive-Ramos A; Seoane S; Ocaña A; Pandiella A; Montero JC
Mol Oncol; 2017 Dec; 11(12):1788-1805. PubMed ID: 29032615
[TBL] [Abstract][Full Text] [Related]
25. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
26. The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
Appel CK; Gallego-Pedersen S; Andersen L; Blancheflor Kristensen S; Ding M; Falk S; Sayilekshmy M; Gabel-Jensen C; Heegaard AM
Sci Rep; 2017 Jul; 7(1):4792. PubMed ID: 28684771
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
El Sayed I; Helmy MW; El-Abhar HS
Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
[TBL] [Abstract][Full Text] [Related]
28. Src family kinase targeting in head and neck tumor cells using SU6656, PP2 and dasatinib.
Vu AT; Akingunsade L; Hoffer K; Petersen C; Betz CS; Rothkamm K; Rieckmann T; Bussmann L; Kriegs M
Head Neck; 2023 Jan; 45(1):147-155. PubMed ID: 36285353
[TBL] [Abstract][Full Text] [Related]
29. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
30. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition.
Rose MM; Nassar KW; Sharma V; Schweppe RE
Med Oncol; 2023 Sep; 40(10):299. PubMed ID: 37713162
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin Enhances the Anti-Cancer Effect of Dasatinib by Suppressing Src/PI3K/mTOR Pathway in NSCLC Cells.
Chen B; Xu X; Luo J; Wang H; Zhou S
PLoS One; 2015; 10(6):e0129663. PubMed ID: 26061184
[TBL] [Abstract][Full Text] [Related]
32. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
33. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
Choi KM; Cho E; Bang G; Lee SJ; Kim B; Kim JH; Park SG; Han EH; Chung YH; Kim JY; Kim E; Kim JY
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291786
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
[TBL] [Abstract][Full Text] [Related]
35. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients.
Kim YJ; Hong S; Sung M; Park MJ; Jung K; Noh KW; Oh DY; Lee MS; Oh E; Shin YK; Choi YL
Oncotarget; 2016 Dec; 7(50):82876-82888. PubMed ID: 27756880
[TBL] [Abstract][Full Text] [Related]
36. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Rice L; Lepler S; Pampo C; Siemann DW
Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
[TBL] [Abstract][Full Text] [Related]
37. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
38. [The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
Wang Z; Li L; Shao Z; Xie H; Yang F; Zhou N
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):595-9. PubMed ID: 27126935
[TBL] [Abstract][Full Text] [Related]
39. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
40. Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Inge LJ; Fowler AJ; Paquette KM; Richer AL; Tran N; Bremner RM
J Thorac Cardiovasc Surg; 2013 Feb; 145(2):531-8. PubMed ID: 23142123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
